Market Access News | pharmaphorum

News

Lilly's Inluriyo is the second oral SERD to reach the US market for ESR1-mutated breast cancer, setting up a market tussle with Menarini's Orserdu.

News

After all the threats, it seems President Trump's tariffs on pharmaceuticals are coming to fruition, and a lot sooner than expected.

News

AstraZeneca has elevated its challenge to Medicare drug price negotiation powers to the Supreme Court of the US.

News

The UK government has celebrated the opening of Moderna's £150m vaccines facility, but storm clouds continue to gather on the issue of drug pricing.

News

Biogen's efforts to defend its SMA business have been dealt a setback after the FDA declined to approve a high-dose version of Spinraza.

News

Lilly has named Houston as the second of four locations for new manufacturing facilities that are central to a $27bn investment programme in the US.